Race Oncology Ltd. (RAC) Price & Analysis

Compare

32 Followers

RAC Stock Chart & Stats

AU$2.70

-AU$0.03(-2.27%)

At close: Jan 09 4:00 PM EST

AU$2.70

-AU$0.03(-2.27%)

Day’s Range― - ―

52-Week RangeAU$0.92 - AU$4.90

Previous CloseN/A

Volume68.10K

Average Volume (3M)373.28K

Market Cap

AU$390.30M

Enterprise ValueAU$376.24M

Total Cash (Recent Filing)AU$13.67M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.51

Next Earnings

Mar 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding181,535,260

10 Day Avg. Volume310,625

30 Day Avg. Volume373,283

Financial Highlights & Ratios

PEG Ratio0.63

Price to Book (P/B)12.69

Price to Sales (P/S)33.63

P/FCF Ratio-44.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero Debt Capital StructureA zero-debt balance sheet materially reduces refinancing and interest-rate risk, giving management durable financial flexibility to fund clinical programs, pursue partnerships, or bridge to milestones without immediate leverage pressures. It strengthens solvency during prolonged R&D timelines.

High FY2025 Gross MarginA very strong gross margin indicates high revenue quality and favorable cost of goods for whatever commercial or partner-derived revenues exist. If durable, this provides scalability—revenue growth could flow more directly to operating leverage, improving path to sustainable profitability.

Narrowing Losses And Improved BurnProgress toward narrower losses and a lower cash burn rate signals management can better align spend with milestones. Sustained improvement reduces near-term financing needs and lengthens runway, lowering the structural funding risk inherent in early-stage biotech development.

Bears Say

Persistent Negative Cash FlowConsistent negative operating and free cash flow is a structural weakness: it forces repeated capital raises or partnership deals, dilutes shareholders, and constrains long-term investment. For a clinical-stage biotech, ongoing cash burn directly limits ability to advance programs without external funding.

Volatile And Falling RevenueSharp, volatile revenue undermines predictability and suggests commercialization is uneven or early-stage. This hampers planning for R&D and SG&A investments, complicates milestone-based partnership negotiations, and increases the probability that recurring funding will be required to sustain operations.

Eroding Equity And Negative ROEA declining equity base and materially negative ROE reflect persistent value erosion and indicate shareholder capital is not generating returns. Structurally, this elevates the risk of dilutive capital raises and means long-term shareholder value depends on binary clinical or partnership outcomes rather than steady operational profitability.

Race Oncology Ltd. News

Racura fast-tracks RC220 cardioprotection data with novel blood test in CPACS trial

Race Oncology Ltd. ( ($AU:RAC) ) has provided an update. Racura Oncology has developed a new blood-based molecular...

7d ago

RAC

Racura Oncology Launches Selective Share Buy-Back Program

The latest announcement is out from Race Oncology Ltd. ( ($AU:RAC) ). Racura Oncology Ltd has notified the...

12d ago

RAC

Racura Moves to Correct Capital Structure After Option Exercise Error

Race Oncology Ltd. ( ($AU:RAC) ) has issued an update. Racura Oncology has disclosed that a November 2025...

12d ago

RAC

Racura Oncology Seeks ASX Quotation for 23,047 New Ordinary Shares

An update from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology Ltd has applied to...

12d ago

RAC

Racura Oncology Seeks ASX Quotation for 141,645 New Shares

Race Oncology Ltd. ( ($AU:RAC) ) has provided an update. Racura Oncology Ltd has applied to the ASX...

19d ago

RAC

Racura Oncology Secures Key Bisantrene Patent Filings, Expands RC220 Clinical Programs and Bolsters Cash Position

An announcement from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology reported a strong quarter...

20d ago

RAC

Race Oncology Director Increases Shareholding via $500,000 Option Exercise

The latest update is out from Race Oncology Ltd. ( ($AU:RAC) ). Race Oncology has disclosed a change...

26d ago

RAC

Racura Oncology Seeks ASX Quotation for 470,501 New Shares

Race Oncology Ltd. ( ($AU:RAC) ) has issued an update. Racura Oncology Ltd has applied for quotation on...

26d ago

RAC

Race Oncology Seeks ASX Quotation for 27,762 New Ordinary Shares

Race Oncology Ltd. ( ($AU:RAC) ) has shared an announcement. Race Oncology Ltd has applied to the ASX...

1M ago

RAC

Racura Oncology Taps Emory Expertise to Tackle Osimertinib Resistance in Lung Cancer

Race Oncology Ltd. ( ($AU:RAC) ) just unveiled an announcement. Racura Oncology has entered a collaboration with Emory...

1M ago

RAC

RAC FAQ

What was Race Oncology Ltd.’s price range in the past 12 months?

Race Oncology Ltd. lowest share price was AU$0.92 and its highest was AU$4.90 in the past 12 months.

What is Race Oncology Ltd.’s market cap?

Race Oncology Ltd.’s market cap is AU$390.30M.

When is Race Oncology Ltd.’s upcoming earnings report date?

Race Oncology Ltd.’s upcoming earnings report date is Mar 03, 2026 which is in 14 days.

How were Race Oncology Ltd.’s earnings last quarter?

Race Oncology Ltd. released its earnings results on Aug 26, 2025. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.

Is Race Oncology Ltd. overvalued?

According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Race Oncology Ltd. pay dividends?

Race Oncology Ltd. does not currently pay dividends.

What is Race Oncology Ltd.’s EPS estimate?

Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Race Oncology Ltd. have?

Race Oncology Ltd. has 181,535,260 shares outstanding.

What happened to Race Oncology Ltd.’s price movement after its last earnings report?

Race Oncology Ltd. reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.695%.

Which hedge fund is a major shareholder of Race Oncology Ltd.?

Currently, no hedge funds are holding shares in AU:RAC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Race Oncology Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-27.89%

Trailing 12-Months

Asset Growth

-13.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Race Oncology Ltd.

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.